Welcome to our dedicated page for Incyte news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte stock.
News for Incyte Genomics Inc (Nasdaq: INCY), operating as Incyte Corporation, centers on its activities as a global biopharmaceutical company focused on Oncology and Inflammation & Autoimmunity. Company releases describe a portfolio of first‑in‑class medicines and a pipeline of proprietary therapeutics, making INCY news particularly relevant for investors and healthcare observers following cancer and immune‑related drug development.
Recent headlines highlight late-stage clinical trial results and regulatory milestones. Incyte has reported positive topline data from the Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) plus lenalidomide and R‑CHOP as first‑line therapy for diffuse large B‑cell lymphoma, meeting primary and key secondary endpoints. Other news covers European Commission and Japanese approvals of Minjuvi in combination regimens for relapsed or refractory follicular lymphoma and DLBCL, underscoring the company’s role in B‑cell lymphoma treatment.
In immuno‑oncology, Incyte Biosciences Japan G.K. has announced approval of Zynyz (retifanlimab) with platinum‑based chemotherapy as first‑line treatment for advanced squamous cell carcinoma of the anal canal, following earlier U.S. approval in a similar setting. Additional coverage describes submissions to European regulators and the broader POD1UM clinical program evaluating retifanlimab across solid tumors.
News flow also features pipeline updates for INCA033989, a first‑in‑class mutCALR‑targeted monoclonal antibody for myeloproliferative neoplasms. Incyte has disclosed Breakthrough Therapy designation from the U.S. FDA for essential thrombocythemia with Type 1 CALR mutations, along with Phase 1 data in ET and myelofibrosis showing hematologic responses, spleen volume reductions, symptom improvements and safety findings.
Beyond R&D, Incyte issues releases on leadership changes, board transitions, inducement equity grants and participation in major healthcare investor conferences. For investors and analysts, the INCY news page provides a centralized view of clinical, regulatory, corporate governance and capital markets developments affecting the company.
Incyte (NASDAQ:INCY) has received FDA approval for Opzelura® (ruxolitinib) cream 1.5% to treat mild to moderate atopic dermatitis in non-immunocompromised children aged 2-11 years. This marks Opzelura's third FDA approval, making it the first topical JAK inhibitor approved for pediatric atopic dermatitis in the U.S.
The approval is based on the Phase 3 TRuE-AD3 trial, which demonstrated significant efficacy in achieving Investigator's Global Assessment-treatment success and 75% improvement in the Eczema Area and Severity Index. The treatment showed a consistent safety profile with no new concerns identified. This expansion addresses an estimated 2-3 million patients aged 2-11 in the U.S. affected by atopic dermatitis.
Incyte (Nasdaq:INCY) announced promising 24-week interim data from its Phase 3 STOP-HS clinical trials for povorcitinib, an oral JAK1 inhibitor for hidradenitis suppurativa (HS). The trials demonstrated statistically significant improvements in patients with moderate to severe HS.
Key findings include: Nearly 60% of patients achieved HiSCR50 (≥50% reduction in inflammatory lesions) at Week 24. Additional endpoints showed 31.0%-40.3% achieved HiSCR75, 13.8%-27.7% reached HiSCR90, and 9.2%-21.3% attained HiSCR100. Notably, 62%-70% of patients reported mild or no pain by Week 24.
The data will support regulatory submissions in Europe (2025) and the United States (early 2026). The treatment demonstrated a consistent safety profile with previous data, with both 45mg and 75mg doses well-tolerated.
Incyte (NASDAQ:INCY) will present new data from its dermatology portfolio at the EADV 2025 Congress in Paris from September 17-20. The presentations will highlight key findings from multiple clinical trials, including a late-breaking presentation of 24-week data from the Phase 3 STOP-HS trial of povorcitinib for hidradenitis suppurativa.
The company will showcase results across multiple dermatological conditions, featuring data on povorcitinib (an oral JAK1 inhibitor) and ruxolitinib cream (Opzelura®) (a topical JAK1/2 inhibitor). Presentations will cover treatments for conditions including hidradenitis suppurativa, prurigo nodularis, vitiligo, and atopic dermatitis.
Incyte (Nasdaq:INCY) has launched HS TRUTHS, an educational campaign focused on revealing the realities of living with hidradenitis suppurativa (HS), a chronic inflammatory skin condition. The campaign features authentic stories from HS patients highlighting both physical and emotional impacts of the disease.
HS affects approximately 1% of the population and is characterized by painful nodules and abscesses that can cause permanent tissue damage. The condition significantly impacts patients' daily lives, with diagnosis often taking 7-10 years. A recent survey revealed that 75% of patients experience negative emotions during healthcare discussions.
The initiative aims to improve patient-provider communication and increase understanding of HS's comprehensive impact through unfiltered patient testimonials.
Incyte (Nasdaq: INCY) announced equity inducement awards for Soni Basi, the company's new Executive Vice President and Chief Human Resources Officer. The compensation package includes:
- 29,230 stock options at $84.76 per share, vesting over 4 years
- 6,506 restricted stock units (RSUs), vesting 25% annually over 4 years
- 16,265 target performance shares based on 3-year TSR performance, potentially earning 0-200% of target
The awards were granted under Incyte's 2024 Inducement Stock Incentive Plan and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Incyte (Nasdaq:INCY) has appointed Soni Basi as Executive Vice President and Chief Human Resources Officer (CHRO), effective August 25, 2025. As a key member of the Executive Leadership Team, Basi will lead the company's global HR strategy, focusing on talent acquisition, organizational design, and professional development.
Basi brings over 25 years of experience in global HR and business leadership, previously serving as CHRO at Edelman where she managed 200+ HR professionals. Her prior experience includes leadership roles at AIG, Allergan Pharmaceuticals, The Estée Lauder Companies, and Schering-Plough. She succeeds Paula Swain, who has retired from her position as Executive Vice President and Head of Human Resources.
Incyte (Nasdaq:INCY) has announced its participation in three major healthcare investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference (September 3), Wells Fargo Healthcare Conference (September 4), and Morgan Stanley 23rd Annual Global Healthcare Conference (September 9).
All presentations will be accessible through live webcasts on Investor.Incyte.com and will remain available for replay for 30 days following each event.
Incyte (NASDAQ:INCY) announced that Executive Vice President and Chief Financial Officer Christiana Stamoulis will step down effective September 16, 2025, to pursue another opportunity. Stamoulis, who joined the company in 2019, will assist with the transition period while Incyte searches for her successor.
CEO Bill Meury expressed gratitude for Stamoulis's contributions and emphasized the company's focus on finding a strategic leader to execute their long-term growth plan. Importantly, Incyte reaffirmed its 2025 financial guidance previously announced on July 29, 2025, stating that its financial position and strategic direction remain unchanged.
Incyte (NASDAQ:INCY) reported strong Q2 2025 financial results with total revenues of $1.22 billion, up 16% year-over-year. Key product performance includes Jakafi revenues of $764 million (+8% Y/Y) and Opzelura revenues of $164 million (+35% Y/Y).
The company achieved significant regulatory milestones with FDA approvals for Zynyz in squamous cell anal carcinoma and Monjuvi in follicular lymphoma. Notable pipeline progress includes positive Phase 1 data for INCA033989 in essential thrombocythemia and advancement of multiple Phase 3 programs.
Incyte raised its full-year 2025 guidance for Jakafi to $3.0-3.05 billion (previously $2.95-3.0 billion) and Other Oncology to $500-520 million (previously $415-455 million). The company also announced Bill Meury as new CEO, succeeding retiring Hervé Hoppenot.
Incyte (NASDAQ:INCY) announced it will present initial data from its oncology portfolio at the ESMO Congress 2025 in Berlin, October 17-21. The presentations will feature two key developments: INCA33890, a TGFβR2×PD-1-directed bispecific antibody for advanced solid tumors, and INCB161734, a novel oral inhibitor targeting G12D-mutated KRAS.
The company will deliver an oral presentation on INCB161734's Phase 1 results on October 19, and a mini oral presentation on INCA33890's Phase 1 study on October 17. Additionally, Incyte will present data on retifanlimab combinations for head and neck cancer treatment.